Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neuphoria Therapeutics (NEUP) Research & Development (2024 - 2025)

Neuphoria Therapeutics (NEUP) has disclosed Research & Development for 2 consecutive years, with $697723.0 as the latest value for Q4 2025.

  • On a quarterly basis, Research & Development fell 59.83% to $697723.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $9.7 million, a N/A change, with the full-year FY2025 number at $9.0 million, down 4.38% from a year prior.
  • Research & Development was $697723.0 for Q4 2025 at Neuphoria Therapeutics, down from $3.8 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $3.8 million in Q3 2025 to a low of $697723.0 in Q4 2025.